The Quality Assurance Review Center (QARC) will continue its role to assure the integrity of the radiation therapy data of the Clinical Cooperative Groups it serves. It will provide comprehensive case management of every protocol patient. Using QARC's self-constructed, Access- based, database to initiate, track and record the status and data of each patient, QARC will promote improved compliance rates with the radiation therapy aspects of Groups protocols. Data submission will be pursued pro-actively; QARC's Clinical Research Associates (CRA) and dosimetrists will review the adequacy and timeliness of submitted data, and educate the treating institutions of the requirements. Physician review of target volumes and physics review of dosimetry, performed before or at the beginning of treatment, as required for most protocols, will increase the adherence to radiation therapy guidelines. Protocol patient data will be more complete and more compliant; deviation rates will be decreased by QARC's activities. The validity of the data for analyses will be increased. QARC will guide the cooperative groups in the introduction of new technologies, and will participate in translating their complexities into multi-institutional clinical trials. Through individual physician interactions, summary presentations, and support of archival research, QARC will be a resource to the Groups, and to individual investigators. QARC will endeavor to maintain and expand its modes of communication, to be flexible and accommodating, so that participation in clinical trials may include institutions with a variety of capabilities. Development of the QARC.org Website will enhance the communication between QARC and the Groups and the institutions. Having forms and treatment planning cases, and examples of appropriate target volumes and treatment fields available for viewing on the Website will increase efficiency and will increase adherence to protocol guidelines. Through QARC's activities, overall standards of care in radiation therapy will improve.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA029511-24
Application #
6626544
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1989-08-15
Project End
2006-12-31
Budget Start
2003-01-01
Budget End
2003-12-31
Support Year
24
Fiscal Year
2003
Total Cost
$1,563,822
Indirect Cost
Name
University of Massachusetts Medical School Worcester
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
603847393
City
Worcester
State
MA
Country
United States
Zip Code
01655
FitzGerald, Thomas J; Bishop-Jodoin, Maryann (2018) Hodgkin Lymphoma: Differences in Treatment Between Europe and the United States/North America: Evolving Trends in Protocol Therapy. Clin Med Insights Oncol 12:1179554918754885
O'Neill, Allison F; Towbin, Alexander J; Krailo, Mark D et al. (2017) Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children's Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children's Oncology Group. J Clin Oncol 35:3465-3473
Katzenstein, Howard M; Furman, Wayne L; Malogolowkin, Marcio H et al. (2017) Upfront window vincristine/irinotecan treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 study committee. Cancer 123:2360-2367
Garg, Madhur K; Zhao, Fengmin; Sparano, Joseph A et al. (2017) Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol 35:718-726
Sparano, Joseph A; Lee, Jeannette Y; Palefsky, Joel et al. (2017) Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium Trial. J Clin Oncol 35:727-733
Wozniak, Antoinette J; Moon, James; Thomas Jr, Charles R et al. (2015) A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer 16:340-7
Trippett, Tanya M; Schwartz, Cindy L; Guillerman, R Paul et al. (2015) Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report. Pediatr Blood Cancer 62:60-4
Dharmarajan, Kavita V; Friedman, Debra L; Schwartz, Cindy L et al. (2015) Patterns of relapse from a phase 3 Study of response-based therapy for intermediate-risk Hodgkin lymphoma (AHOD0031): a report from the Children's Oncology Group. Int J Radiat Oncol Biol Phys 92:60-6
Dharmarajan, Kavita V; Friedman, Debra L; FitzGerald, T J et al. (2015) Radiotherapy quality assurance report from children's oncology group AHOD0031. Int J Radiat Oncol Biol Phys 91:1065-71
Servaes, Sabah; Khanna, Geetika; Naranjo, Arlene et al. (2015) Comparison of diagnostic performance of CT and MRI for abdominal staging of pediatric renal tumors: a report from the Children's Oncology Group. Pediatr Radiol 45:166-72

Showing the most recent 10 out of 60 publications